Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate
AGC Biologics is producing vaccine materials for early-stage trials at its Heidelberg facilities
Seattle, March 31, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The CDMO has manufactured phase I clinical trial materials for Allergy Therapeutics’ novel virus-like particle (VLP)-based peanut allergy vaccine candidate (“VLP Peanut”), ahead of trial commencement later this year.
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply. The United States Food & Drug Administration (FDA) recently cleared Allergy Therapeutics Investigational New Drug application (IND), which included data generated in this collaborative effort and granted the VLP Peanut vaccine candidate a clear path to a Phase I product trial in the U.S.
“Allergy Therapeutics is creating a strong vaccine candidate for one of the most common food allergies in the world and we are proud to be helping bring it to this critical phase I trial phase,” said Jean-Baptiste Agnus, Chief Business Officer at AGC Biologics. “This is a shining example of the ability and expertise of our global network to handle some of the most complex products and support our clients advancing through important clinical phases.”
A peanut allergy is one of the most common types of food allergies worldwide, and in the U.S., it is also a leading cause of severe and fatal food-induced anaphylactic reactions. Through this partnership, AGC Biologics will continue to work collaboratively with Allergy Therapeutics to develop the vaccine candidate that has the potential to provide relief for patients that have a critical need.
“This is another key milestone for our VLP Peanut vaccine candidate, and we believe AGC Biologics is a great partner for us as we enter the next stage of bringing this promising immunotherapy to market,” said Manuel Llobet, Chief Executive Officer, Allergy Therapeutics. “We are excited to demonstrate the potential of this vaccine to provide long-term protection and a long-lasting protective immune response.”
AGC Biologics is producing this vaccine material at its state-of-the-art clinical and commercial manufacturing facility in Heidelberg, Germany. The site specializes in Microbial and Plasmid DNA (pDNA) offerings and is one of the company’s central facilities in Europe. The core team at the Heidelberg facility has several decades of experience delivering a wide range of programs, including work with BioNTech to supply COVID-19 vaccine materials.
For more information on AGC Biologics’ offerings visit www.agcbio.com/capabilities.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
About VLP Peanut
VLP Peanut is being developed as a therapy for the treatment of peanut allergy. This novel immunogenic, protective, and non-reactogenic vaccine candidate is based on immunologically optimized Cucumber Mosaic Virus-derived VLPs (CuMVTT) with the major peanut allergen (Arachis hypogaea) (Ara h2) displayed on its surface. Patents behind the technology to treat peanut allergy with VLP Peanut have been granted in multiple territories.
- AGC Biologics, CDMO, Contract Manufacturing Organization, Biologics Contract Development partners with Allergy Therapeutics on peanut vaccine manufacturing
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PRESS RELEASE: NACON: CARANTS*! DRAW CLOSER AND SEE THE FIRST IMAGES OF GREEDFALL 218.5.2022 08:00:00 CEST | Press release
CARANTS*! DRAW CLOSER AND SEE THE FIRST IMAGES OF GREEDFALL 2 Lesquin, 18 May 2022 – After the success of GreedFall, with over 2 million copies sold, NACON and the development studio Spiders are pleased to announce a new game: GreedFall 2. Continuing the winning formula of the first game, GreedFall 2 is an RPG that focuses on story and player choice but also includes new gameplay in the form of more tactical combat and revisits the unique universe created by its predecessor. The story starts three years before the events of the first game and the adventures of De Sardet. This time you play as a native of Teer Fradee, uprooted by force from your island and taken to the continent of Gacane, where the colonists are from. In this old world ravaged by war and scarred by the Malichor plague and the political scheming of the different factions, you must regain your freedom and control of your own destiny. Using diplomacy, cunning or combat, as well as help from allies you make, it's up to you
Millicom announces the terms of its rights offering18.5.2022 08:00:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. Millicom announces the terms of its rights offering Luxembourg, May 18, 2022 – The board of directors of Millicom International Cellular S.A. (“Millicom”, the “Company” or “we”) has today, making use of the authorization provided for in the Company’s articles of association, resolved on a rights offering (the “Rights Offering”) granting preferential subscription rights to existing holders of sharesand Swedish Depositary Receipts (“SDRs”) to subscribe for up to 70,357,088 shares in aggregate (including in theform of SDRs) and hereby announces the terms of the Rights Offering.
AB Klaipėdos nafta (KN) will hold an Investor Conference Webinar to introduce unaudited financial results for the three months of 202218.5.2022 08:00:00 CEST | Press release
KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on the May 27th of 2022 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Mindaugas Kvekšas who will introduce the performance and unaudited financial results of KN for the three months of 2022. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until May 25th to email@example.com How to join the webinar? To join the webinar, please register via following link:https://nasdaq.zoom.us/webinar/register/WN_aVz8e35rRqO1UC5O3WBp4AYou will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case pl
KBC Group: Notification for bondholders and shareholders of KBC Group18.5.2022 08:00:00 CEST | Press release
Notification for bondholders and shareholders of KBC Group Regulated information – 18 May 2022 before trading hours (08h00) Please be informed that following documents will be available on www.kbc.com: - Minutes of the General Meeting of KBC Group dd 5 May 2022 https://www.kbc.com/en/corporate-governance/general-meeting/5-mei-2022.html
Sampo plc’s share buybacks 17/05/202218.5.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 18/05/2022 at 08:30 am Sampo plc’s share buybacks 17/05/2022 On 17/05/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)28,56046.33AQEU41,30446.31CEUX10,74946.33TQEX61,23946.32XHELTOTAL141,85246.32 *rounded to two decimals On 30 March 2022, Sampo announced a share buyback programme of up to a maximum of EUR 250 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 31 March 2022, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 4,961,994 Sampo A shares representing 0.92 per cent of the total number of shares in Sampo plc. Details